Track Docket
Download Docs
Export
Judge 
Party 
Law Firm Epichouse LLC, (First Class Herbalist CBD), In the Matter of
2023094 | Federal Trade Commission
Interested in this case?
Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed
Dec. 17, 2020
Case Flags
Health Care,
Over-the-Counter Drugs and Devices,
Consumer Protection,
Advertising and Marketing,
Health Claims,
Health,
and
Bureau of Consumer Protection
FTC Matter/File Number
2023094
Case Summary
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders setting the agency’s respective complaint is provided below.
Epichouse LLC. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to pay $30,000 to the FTC and notify consumers of the Commission’s order.
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders setting the agency’s respective complaint is provided below.
Epichouse LLC. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to pay $30,000 to the FTC and notify consumers of the Commission’s order.
Case Type
Administrative
Last Updated: 3 years, 3 months ago
| Filing Date | # | Docket Text |
|---|
